TAIPEI, Nov. 7, 2024 /PRNewswire/ — Acer Inc. (TWSE: 2353) announced its financial results for the third quarter of 2024: consolidated revenues were NT$72.69 billion with 8.3% growth quarter-on-quarter (QoQ) and 7.8% growth year-on-year (YoY); gross profits reached NT$7.68 billion, up 6.9% QoQ and 5.2% YoY, with 10.6% margin; operating income was NT$1.60 billion, up 9.2% QoQ and 3.7% YoY, with 2.2% margin; net income[1] was NT$1.50 billion, up 7.2% QoQ; and earnings per share was NT$0.50. Businesses other than computers and displays contributed 26.9% of total group revenues, while public subsidiaries contributed 26.4% of operating income.

For year-to-September, consolidated revenues were NT$198.66 billion with 11.5% growth YoY; gross profits reached NT$21.05 billion, up 11.3% YoY with 10.6% margin; operating income was NT$3.85 billion, up 36.1% YoY with 1.9% margin; net income[1] was NT$4.11 billion, up 5.0% YoY; and earnings per share was NT$1.37. Businesses other than computers and displays contributed 28.0% of total group revenues, while public subsidiaries contributed 36.5% of operating income.

To strengthen the company’s risk management, realize sustainable development goals, and enhance governance, Acer’s Board of Directors approved the reorganization of the former Risk Management Committee to become the “Risk Management and Sustainable Development Committee,” with expanded tasks of overseeing cyber security and corporate sustainability.

About Acer

Founded in 1976, Acer is one of the world’s top ICT companies with a presence in more than 160 countries. As Acer evolves with the industry and changing lifestyles, it is focused on enabling a world where hardware, software and services will fuse with one another, creating ecosystems and opening up new possibilities for consumers and businesses alike. Acer’s 7,700 employees are dedicated to the research, design, marketing, sale, and support of products and solutions that break barriers between people and technology. Please visit www.acer.com for more information.

© 2024 Acer Inc. All rights reserved. Acer and the Acer logo are registered trademarks of Acer Inc. Other trademarks, registered trademarks, and/or service marks, indicated or otherwise, are the property of their respective owners. All offers subject to change without notice or obligation and may not be available through all sales channels. Prices listed are manufacturer suggested retail prices and may vary by location. Applicable sales tax extra.

View original content to download multimedia:https://www.prnewswire.com/news-releases/acer-announces-operating-income-for-q324-at-nt1-60-billion-and-for-year-to-september-at-nt3-85-billion-with-36-1-growth-302298598.html

SOURCE Acer

The end-to-end LLM solution is designed to accelerate AI deployment by integrating out-of-the-box AI functionality into powerful Lenovo infrastructure.NeuroNode equips enterprises with security, autonomy, and scalability, rapidly unlocking the most value from their AI investments.

HONG KONG, Nov. 7, 2024 /PRNewswire/ — Lenovo PCCW Solutions (LPS) announces the launch of NeuroNode, a private Large Language Model (LLM) In-A-Box solution that offers a secure, quick and cost-effective AI solution for enterprises – providing an accessible option for businesses looking to benefit from LLMs. The launch of NeuroNode underscores LPS’ commitment to excellence in IT services, reinforced by being named the No.1 IT Services Provider in Hong Kong by IDC[1].

As the promise of AI-powered digital transformation continues to grow, CIOs are faced with the challenge of finding a secure pathway towards AI adoption. This has resulted in an increasingly cautious outlook towards AI investment, with Lenovo’s 2024 Global CIO Study finding 81% of CIOs leveraging third-party AI tools and proprietary AI tools expressing security as a top concern.

NeuroNode: Smarter and Safer AI at Your Fingertips

NeuroNode, named for its brain-like capabilities, embodies intelligence and agility. Built on Lenovo’s powerful infrastructure and offering a LLM ready out-of-the-box, the solution helps organizations embrace AI as quickly as possible. By enabling powerful AI capabilities on-premises, organizations can have total autonomy and control over their own data without the need to channel anything through the public cloud.

With the simplicity of a box, NeuroNode slots seamlessly into existing technology stacks with minimal infrastructure constraints and can be easily scaled up to meet growing workload demands. NeuroNode comes with native support for leading open source LLMs like Llama 3.1, GLM-4, Pixtral 12B etc. via Open AI compliant API. The simple and interactive interface enables users to input both natural language and images for AI processing with options for pre-built templates to serve unique business needs. Equipped with 4 powerful GPUs at its core, NeuroNode can respond to a typical query by generating a full-length A4 page of text in as little as 10 seconds (A10 GPU model, running Llama3.1 8B model).

NeuroNode empowers organizations to unlock transparent metrics and valuable insights to transform their operations with data privacy ensured. Its robust AI capabilities are designed to meet dynamic industry demands and can be utilized for numerous use cases such as automated content generation, knowledge management, compliance checking, customer service chatbots, and much more.

Dr. Ted Suen, President of LPS, said, “LPS remains committed to driving innovative AI solutions – collaborating closely with Lenovo to fast-track AI adoption for our clients. Our newly launched AI solution, NeuroNode, aims to lower the barriers to entry for enterprises looking for transparent AI value creation and reliable data security.”

As LPS unveils this new solution, the company continues to set the benchmark for IT excellence in Hong Kong. According to IDC Worldwide Semiannual Services Tracker (2024H1 release), LPS leads the Custom Application Development and Systems Integration segments in Hong Kong for 11 consecutive years, commanding 47% and 20.1% market share respectively, with over 9% YoY growth in both. LPS also stands atop the Managed Services segment with an 8.2% YoY revenue growth.

Roger Ling, Associate Vice President, Software, Services and Cloud, IDC Asia/Pacific, said, “As organizations navigate the complexities and opportunities presented by AI, partnering with an experienced and reputable IT service provider is becoming increasingly essential. Such collaborations enable businesses to leverage advanced technologies while ensuring security and operational efficiency, all while effectively addressing local nuances.”

NeuroNode provides a robust and scalable solution for any organization looking to leverage AI technology, with LPS offering further scalability and post-launch support to enhance models through prompt engineering, consulting, and more to help businesses maximize the potential of this solution.

For more information on NeuroNode, please visit here: https://www.lpstech.com/site/en/service/data-ai/neuronode-llm-in-a-box.html

About Lenovo PCCW Solutions (LPS)

LPS is a leading IT and technology solutions provider in the Asia Pacific. We partner with governments and enterprises to achieve digital transformation excellence, driving business growth through our market-leading solutions and industry best practices. As a proud member of Lenovo Group, we have unlocked new synergies with Lenovo’s global reach and technological capabilities. With our 4,000+ team of experts and a strong network of ecosystem partners, LPS is committed to providing end-to-end technology solutions and services, including systems integration, application development and operation, managed services, cloud services, IT outsourcing, and technical services.

To find out more about LPS, please visit www.lpstech.com.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/lps-launches-neuronode-empowering-advanced-ai-for-enterprises-with-on-premises-llm-302298599.html

SOURCE Lenovo PCCW Solutions (LPS)

SHENZHEN, China, Nov. 7, 2024 /PRNewswire/ — MGI Tech Co., Ltd. (“MGI”), a company committed to building core tools and technologies that drive innovation in life science, today announced a commercial partnership with Human Cell Atlas (HCA) consortium to further accelerate the human cell mapping initiative. Aimed to facilitate the wider adoption of single cell sequencing and spatial transcriptomics technologies globally, MGI will expand access to its proprietary products within the HCA network by providing discounted rates to collaborating members.

“Cutting-edge single cell and spatial genomics are important driving forces for the HCA project,” said John Randell, HCA Chief Alliance Officer. “MGI’s involvement in the HCA discount program will enhance the efforts of our collaborative members and help fuel HCA’s progress and new scientific discoveries.”

Under this partnership, HCA members will enjoy more access to MGI’s cost-effective and scalable single cell and spatial omics solutions. In addition, MGI will also provide support to members in experimental design, assay execution, and bioinformatic support when applying MGI’s technologies to their research.

First introduced in 2019, MGI’s single cell series has become one of the company’s main product lines. Based on the core DNBSEQä technology, the series addresses the diverse demand of single cell research by offering users a comprehensive and user-friendly solution. The DNBelab C-TaiM 4 portable droplet generator, the latest addition to MGI’s single cell lineup, is meticulously crafted to facilitate high-throughput single-cell 3’RNA, 5’RNA& V(D)J,ATAC in any setting. This compact but robust device seamlessly integrates dual-bead cell capture, a microfluidic droplet generator, state-of-the-art computing modules, and other advanced technologies to enable intricate genomic analyses anytime anywhere.

Starting June 2024, MGI also became an official distributor of STOmics-related products, opening access to cutting-edge advancements in spatial omics for the scientific community. STOmics’ proprietary Stereo-seq technology has revolutionized spatial multi-omics research with its large field of view, nanoscale resolution, unbiased whole transcriptome capture, and multi-omics solutions. Its applications span diverse fields, including developmental biology, organ atlas, neuroscience, and digital pathology. To date, it has also contributed to over 60 publications in top-tier journals like Cell, Science, Nature, and Cell Research.

“We are proud to support HCA researchers worldwide in this important effort to uncover the intricate details of how the genes in our cells shape life,” said Duncan Yu, President at MGI. “Leveraging MGI’s highly sensitive and specific tools with comprehensive coverage, this partnership will allow the HCA community to push the boundaries of single cell genomics and spatial omics further, with broad implications for scientific discovery and disease research.”

The HCA is a global collaborative research consortium that is creating comprehensive reference maps of all human cells in the healthy body to drive major advances in healthcare and medicine worldwide. Founded in 2016, it has grown to more than 3,600 HCA members from over 100 countries around the world. To date, the global HCA community has profiled tens of millions of cells from nearly 10,000 individuals and produced more than 400 HCA scientific publications, delivering fundamental insights into human biology and diseases.

Over the years, MGI has been empowering scientists and researchers globally in frontier life science research with cutting-edge tools and facilitating advances and discoveries in the understanding of human cells. The company has been actively supporting HCA research as far back as 2018. Notably, in 2019, at a European Molecular Biology Organization (EMBO) workshop on Single Cell Biology, Dr. Sarah Teichmann, co-founder and principal leader of the HCA consortium, shared her systematic evaluation workflow for single-cell RNA sequencing using MGI’s platforms.

Earlier this year, MGI participated in the HCA Single-cell Omics Workshop in Bangkok to connect with members and promote its advanced technology. Following that, the company will be present at the HCA Asia 2024 Meeting, taking place in Hong Kong from December 3 to 4. MGI welcomes researchers and scientists worldwide to participate for exchanges of ideas and to explore partnership opportunities.

About MGI MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various other industries.

Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and establishing research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future.

For more information, please visit the MGI website or connect with us on Twitter, LinkedIn or YouTube.

View original content to download multimedia:https://www.prnewswire.com/news-releases/mgi-tech-partners-with-the-human-cell-atlas-to-further-advance-worldwide-human-cell-mapping-efforts-302298601.html

SOURCE MGI Tech